Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Accelerating Access to Medicine Through Research, Collaboration, and Innovation

Healthcare leaders are bridging systemic gaps between groundbreaking research and underserved communities through coordinated innovation

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Brian Urban · Access to MedicineBrian UrbanFinthriveHealthcare Access
Share

Key takeaways

01

Healthcare leaders are bridging systemic gaps between groundbreaking research and underserved communities through coordinated innovation

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Accelerating access to medicine for underserved communities, with a goal of diversity and inclusion, is possible. The healthcare community can turn vision into reality through research, collaboration, and innovation.

The healthcare community can turn vision into reality through research, collaboration, and innovation.

As the healthcare landscape continuously morphs, the spotlight is now on how systemic inequities impact the journey from medical research to accessible patient care. The global health crisis has exacerbated the urgency for a more inclusive approach, revealing stark representation gaps, particularly in clinical trials. A startling statistic from the Tufts Center for the Study of Drug Development unveils that a mere 5% of the U.S. populace partakes in clinical trials, with Caucasians making up 75% of this demographic. This glaring lack of diversity not only underscores a failure in representation but also threatens the universal applicability of trial outcomes, leaving the needs of many unaddressed.

As healthcare stakeholders grapple with these challenges, a critical question surfaces: How can the melding of research collaboration and innovation fast-track the availability of medical interventions while concurrently ensuring a diverse and representative participation in clinical trials?

In Healthcare Rethink, a FinThrive Podcast, host Brian Urban orchestrates a deep-dive discussion with industry frontrunners – Ramita Tandon, the Chief Clinical Trials Officer from Walgreens Boots Alliance, Dr. Mitesh Rao, the CEO and Founder of OMNY Health, and Jaime Smith, Ph.D., the Global Head of Scientific Data at Parexel. Together, they traverse the intricate avenues of accelerating medication accessibility through synergistic research endeavors and innovation, with a unique lens on amplifying diversity in clinical trials to reflect the kaleidoscope of the populace it aims to serve.

Urban, Tandon, Rao, and Smith discuss the following topics:

  • Unveiling the systemic barriers in clinical trial diversity and the collaborative ventures to navigate these challenges
  • The cardinal role of community pharmacies like Walgreens in local healthcare delivery and clinical trial education
  • The potential of real-world data and strategic alliances in democratizing access to clinical trials and healthcare resources

Ramita Tandon is a medical research trailblazer focusing on disrupting the conventional clinical development life cycle. Dr. Mitesh Rao brings a robust background as an emergency medicine physician turned health system executive, with an enduring passion for leveraging data to bridge organizational silos and enhance patient inclusion in research opportunities. Jaime Smith's journey from a budding economist to a leader in the healthcare sector's statistical research and predictive modeling embodies a relentless pursuit of impactful research and a vision for global healthcare innovation.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Brian Urban
Brian UrbanDirector of Innovation & Emerging Markets

Brian Urban has a deep skill set in health promotion and product development for rare disease and senior populations with Large Health Plans and Specialty Pharmacy. Urban has served as a speaker on such topics for the Alzheimer’s Association, Obediah Cole Prostate Cancer Foundation, Cigna Corp and Utica University Institute for the study of integrative healthcare. Urban has received a Masters of Science in Exercise Physiology-Health Promotion, Masters of Business Administration in Market Development and is currently completing a Masters in Public Health at Dartmouth College. Urban is currently a research-fellow sponsored by a Robert Wood Johnson Grant supporting Utica University public health research in Upstate New York.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

OpenAI’s ChatGPT for Healthcare is getting wired into Epic

OpenAI’s ChatGPT for Healthcare is getting wired into Epic

ChatGPT for Healthcare can now read from Epic. UCSF Health is piloting the read-only integration, according to Fierce Healthcare and Becker’s Hospital Review. For CIOs, the work is permissions, auditability, and clinical validation in Epic workflows.

  • 01The “read-only” label doesn’t remove governance work, it moves it to permissions mapping, audit logs, and connector scope design inside Epic-supported workflows.
  • 02OpenAI’s published clinician review results (99.1% rated safe across 4,363 ratings) are a useful benchmark, but they still need local validation on your own note templates, meds workflows, and specialty mix.

Sep 7, 2026

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

Brian Urban
Brian Urban

Director of Innovation & Emerging Markets

Brian Urban has a deep skill set in health promotion and product development for rare disease and senior populations with Large Health Plans and Specialty Pharmacy. Urban has served as a speaker on such topics for the Alzheimer’s Association, Obediah Cole Prostate Cancer Foundation, Cigna Corp and Utica University Institute for the study of integrative healthcare. Urban has received a Masters of Science in Exercise Physiology-Health Promotion, Masters of Business Administration in Market Development and is currently completing a Masters in Public Health at Dartmouth College. Urban is currently a research-fellow sponsored by a Robert Wood Johnson Grant supporting Utica University public health research in Upstate New York.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512